771 related articles for article (PubMed ID: 23477830)
21. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
[TBL] [Abstract][Full Text] [Related]
22. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
23. MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
Aida S; Sonobe Y; Tanimura H; Oikawa N; Yuhki M; Sakamoto H; Mizuno T
Cancer Lett; 2017 Nov; 409():116-124. PubMed ID: 28923400
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.
Sharma A; Shah SR; Illum H; Dowell J
Drugs; 2012 Dec; 72(17):2207-22. PubMed ID: 23116250
[TBL] [Abstract][Full Text] [Related]
25. Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics.
Ferraz LS; Costa RTD; Costa CAD; Ribeiro CAJ; Arruda DC; Maria-Engler SS; Rodrigues T
Biochem Pharmacol; 2020 Aug; 178():114104. PubMed ID: 32562785
[TBL] [Abstract][Full Text] [Related]
26. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
27. Elucidating distinct roles for NF1 in melanomagenesis.
Maertens O; Johnson B; Hollstein P; Frederick DT; Cooper ZA; Messiaen L; Bronson RT; McMahon M; Granter S; Flaherty K; Wargo JA; Marais R; Cichowski K
Cancer Discov; 2013 Mar; 3(3):338-49. PubMed ID: 23171796
[TBL] [Abstract][Full Text] [Related]
28. FBXW7 regulates a mitochondrial transcription program by modulating MITF.
Abbate F; Badal B; Mendelson K; Aydin IT; Serasinghe MN; Iqbal R; Mohammed JN; Solovyov A; Greenbaum BD; Chipuk JE; Celebi JT
Pigment Cell Melanoma Res; 2018 Sep; 31(5):636-640. PubMed ID: 29665239
[TBL] [Abstract][Full Text] [Related]
29. New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.
Ferretta A; Maida I; Guida S; Azzariti A; Porcelli L; Tommasi S; Zanna P; Cocco T; Guida M; Guida G
Biochim Biophys Acta; 2016 Nov; 1863(11):2710-2718. PubMed ID: 27542908
[TBL] [Abstract][Full Text] [Related]
30. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
Ngeow KC; Friedrichsen HJ; Li L; Zeng Z; Andrews S; Volpon L; Brunsdon H; Berridge G; Picaud S; Fischer R; Lisle R; Knapp S; Filippakopoulos P; Knowles H; Steingrímsson E; Borden KLB; Patton EE; Goding CR
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8668-E8677. PubMed ID: 30150413
[TBL] [Abstract][Full Text] [Related]
31. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Wellbrock C; Marais R
J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
[TBL] [Abstract][Full Text] [Related]
32. A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo.
Lister JA; Capper A; Zeng Z; Mathers ME; Richardson J; Paranthaman K; Jackson IJ; Elizabeth Patton E
J Invest Dermatol; 2014 Jan; 134(1):133-140. PubMed ID: 23831555
[TBL] [Abstract][Full Text] [Related]
33. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
34. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.
Kono M; Dunn IS; Durda PJ; Butera D; Rose LB; Haggerty TJ; Benson EM; Kurnick JT
Mol Cancer Res; 2006 Oct; 4(10):779-92. PubMed ID: 17050671
[TBL] [Abstract][Full Text] [Related]
35. BRAF-mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib.
Nagasawa I; Kunimasa K; Tsukahara S; Tomida A
Biochem Biophys Res Commun; 2017 Jan; 482(4):1491-1497. PubMed ID: 27965097
[TBL] [Abstract][Full Text] [Related]
36. Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition.
Webster DE; Barajas B; Bussat RT; Yan KJ; Neela PH; Flockhart RJ; Kovalski J; Zehnder A; Khavari PA
Genome Res; 2014 May; 24(5):751-60. PubMed ID: 24443471
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.
Haq R; Fisher DE; Widlund HR
Clin Cancer Res; 2014 May; 20(9):2257-63. PubMed ID: 24610826
[TBL] [Abstract][Full Text] [Related]
38. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
39. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
[TBL] [Abstract][Full Text] [Related]
40. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
